more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$119.39 USD

+1.50 (1.27%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

Top 28% (71 out of 250)

Industry: Medical - Products

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

5 Stocks Trading Near 52-Week High With More Room to Run

by Zacks Equity Research Published on August 13,2019

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research Published on August 06,2019

Is (ABT) Outperforming Other Medical Stocks This Year?

ABTPositive Net Change

The Zacks Analyst Blog Highlights: Abbott, Netflix, Philip Morris, United Technologies and Novartis

by Zacks Equity Research Published on July 22,2019

The Zacks Analyst Blog Highlights: Abbott, Netflix, Philip Morris, United Technologies and Novartis

tech-stocks

Top Research Reports for Abbott, Netflix & Philip Morris

by Mark Vickery Published on July 19,2019

Today's Research Daily features new research reports on 16 major stocks, including Abbott (ABT), Netflix (NFLX) and Philip Morris (PM).

Company News for Jul 18, 2019

by Zacks Equity Research Published on July 18,2019

Companies In The News Are: ABT, USB, ERIC, TXT

IVD Market Sustains Momentum: 3 Stocks in Focus

by Trina Mukherjee Published on July 18,2019

In-vitro Diagnostics has successfully proven itself to be the best diagnostic procedures. So, investors can add stocks from this space to their watchlist.

medical

Abbott (ABT) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research Published on July 18,2019

Abbott (ABT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

ABTPositive Net Change

Abbott (ABT) Tops Q2 Earnings Estimates, Lifts EPS Guidance

by Zacks Equity Research Published on July 17,2019

Abbott (ABT) registers strong Cardiovascular and Neuromodulation sales on double-digit growth in Electrophysiology, Heart Failure and Structural Heart.

Mixed Housing Data for June

by Zacks Equity Research Published on July 17,2019

Mixed Housing Data for June

Housing Starts, Building Permits Mixed; Q2 for BAC, USB, ABT

by Mark Vickery Published on July 17,2019

Housing Starts were up slightly for June, but Building Permits disappointed.

Abbott (ABT) Q2 Earnings Surpass Estimates

by Zacks Equity Research Published on July 17,2019

Abbott (ABT) delivered earnings and revenue surprises of 2.50% and -0.10%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

ABTPositive Net Change

US-India Trade Tensions Rise: 3 Stocks in the Line of Fire

by Sreyoshi Mukherjee Published on July 17,2019

As India moves toward self-sufficiency, U.S. MedTech bigwigs fret over possible losses.

medical

5 Stocks with Spectacular Earnings Charts

by Tracey Ryniec Published on July 16,2019

These companies aren't just beating on earnings, their stocks are also on fire, hitting new 5-year highs.

Abbott MitraClip G4 Gets FDA Nod, Valve Repair Options Expand

by Zacks Equity Research Published on July 16,2019

The FDA approval for MitraClip G4 is expected to enhance Abbott's (ABT) cardiac treatment portfolio.

medical

Will Abbott's (ABT) Q2 Earnings Gain From Overall Growth?

by Zacks Equity Research Published on July 15,2019

Abbott's (ABT) consistent rise on a strong Diabetes Care business performance is seen over the last few quarters.

ABT or BIO: Which Stock Has Better Potential Right Now?

by Zacks Equity Research Published on July 15,2019

Abbott (ABT) scores higher than Bio-Rad (BIO) in terms of valuation and one-year price performance.

medical

Bull of the Day: Penumbra (PEN)

by Kevin Cook Published on July 12,2019

This $6 billion innovator removes blood clots and the deadly shadow of stroke with catheter-based aspiration technologies

medical

Abbott (ABT) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research Published on July 10,2019

Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.